
Exact Sciences (EXAS) Stock Forecast & Price Target
Exact Sciences (EXAS) Analyst Ratings
Bulls say
Exact Sciences is positioned for significant growth, with its flagship Cologuard screening test expected to increase its market share from approximately 15% to over 40%, bolstered by strong demand and higher average selling prices. The company has demonstrated robust financial performance, achieving a 22% year-over-year growth in its core screening business, alongside recent improvements towards generating positive Adjusted EBITDA. With ambitious plans to scale screening efforts, targeting at least 30 million people by 2027, and a successful digital marketing campaign for its Cancerguard blood test, Exact Sciences is on track for continued revenue acceleration.
Bears say
Exact Sciences faces significant challenges that contribute to a negative outlook regarding its stock performance. The company's reliance on promotional marketing for Cologuard demand raises concerns about sustainability, especially given its historical pattern of net losses, casting doubt on its ability to achieve consistent GAAP profitability. Additionally, the projected revenue of $4.0 billion for 2027 falls short of targets, despite potential positive impacts from new agreements and product offerings, highlighting uncertainties within the company's financial growth trajectory.
This aggregate rating is based on analysts' research of Exact Sciences and is not a guaranteed prediction by Public.com or investment advice.
Exact Sciences (EXAS) Analyst Forecast & Price Prediction
Start investing in Exact Sciences (EXAS)
Order type
Buy in
Order amount
Est. shares
0 shares